ChemoCentryx, Inc. (CCXI) was a big mover last session, as its shares rose almost 6% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This continues the uptrend for the company since Dec 18, as the stock is now up over 7%.
In the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
ChemoCentryx currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Some better-ranked medical stocks include Lannett Company, Inc. (LCI), Jazz Pharmaceuticals Plc (JAZZ) and NuVasive, Inc. (NUVA). All three companies carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment